Researchers propose model linking senescent mesenchymal stromal cells to stem cell aging via chemokine dysregulation

A scientific review published in Aging Cell proposes that senescent mesenchymal stromal cells act as amplifiers of tissue aging by dysregulating chemokine signaling, highlighting senolytics and cell rejuvenation as potential restorative therapies.

A review published in the journal Aging Cell by researchers at Simon Fraser University synthesizes literature surrounding mesenchymal stromal cells (MSCs) and their role in the stem cell niche during aging.

The authors outline a model where age-associated cellular, metabolic, and inflammatory stressors cause tissue-resident MSCs to undergo senescence.

This senescent state dysregulates chemokine synthesis, generating a chronic inflammatory profile that disrupts supportive paracrine signaling to resident stem cells, ultimately leading to progressive stem cell dysfunction and decreased regenerative capacity.

MSCs are critical regulators of the stem cell microenvironment, integrating metabolic, paracrine, and inflammatory cues to manage tissue homeostasis.

Characterizing MSC senescence as an intermediate amplifier of tissue aging establishes clear intervention points, particularly through the use of senolytics, MSC rejuvenation, and chemokine-directed therapies.

The proposed model provides a mechanistic rationale for therapeutic pipelines focused on clearing senescent cells or reprogramming cells to restore native microenvironment signaling.

Translational strategies in the longevity sector may increasingly focus on the restoration of niche-supportive paracrine signals rather than addressing stem cell intrinsic aging in isolation.

Preclinical studies evaluating whether senolytic or reprogramming interventions can successfully normalize MSC-derived chemokine signaling and rescue native stem cell regenerative capacity in vivo.